Patient accrual into chemotherapy trials in non-small cell lung cancer

Price, Allan; Price, A
June 2000
Thorax;Jun2000, Vol. 55 Issue 6, p447
Academic Journal
No abstract available.


Related Articles

  • Chemotherapy in the treatment of non-small cell lung cancer. Hainsworth, John D. // American Family Physician;5/1/1997, Vol. 55 Issue 6, p2265 

    Focuses on the treatment of non-small cell lung cancer in the United States. Effective treatment of metastatic non-small cell lung cancer; Outcome of randomized trials comparing chemotherapy with supportive care in patients with non-small cell lung cancer; Locally advanced unresectable cancer;...

  • Vinflunine noninferior to docetaxel for refractory NSCLC.  // Hem/Onc Today;4/25/2010, Vol. 11 Issue 8, p22 

    The article examines a phase-3 trial, which showed that vinflunine is noninferior to docetaxel in treating patients with non-small cell lung cancer whose platinum-based first-line chemotherapy failed.

  • EORTC Protocol 08012.  // Oncologie;sep2004 Supplement 7, Vol. 6, pS199 

    Presents information on a clinical trial of surgical resection with or without pre-operative chemotherapy in patients with operable non-small cell lung cancer of any stage. Results.

  • Prognostic Factors in Advanced Non-small Cell Lung Cancer: Elevated Serum Levels of Neuron Specific Enolase Indicate Poor Prognosis. Maeda, Tadashi; Ueoka, Hiroshi; Tabata, Masahiro; Kiura, Katsuyuki; Shibayama, Takuo; Gemba, Kenichi; Takigawa, Nagio; Hiraki, Akio; Katayama, Hideki; Harada, Mine // Japanese Journal of Clinical Oncology;Dec2000, Vol. 30 Issue 12, p534 

    Discusses the resistance of non-small cell lung cancer (NSCLC) to chemotherapy and the factors that affect the prognosis of advanced NSCLC patients. Clinical trials conducted by the Okayama Lung Cancer Study Group using multivariate analysis; Factors useful in predicting the survival of...

  • Adding Bevacizumab to Chemotherapy Prolongs Lung Cancer Survival, Trial Finds. Travis, Kate; Zielinski, Sarah L. // JNCI: Journal of the National Cancer Institute;4/20/2005, Vol. 97 Issue 8, p556 

    Reports on the preliminary results of a U.S. clinical trial concerning the effect of adding bevacizumab to standard chemotherapy for patients with non-small cell lung cancer. Prolongation of lung cancer survival; Information on the subjects of the study; Significance of the findings.

  • Chemotherapy Combined with Chest Irradiation for Locally Advanced Non-Small Cell Lung Cancer. Hide, Daniel C. // Annals of Internal Medicine;11/1/91, Vol. 115 Issue 9, p737 

    Editorial. Discusses the use of chemotherapy with chest irradiation for the treatment of locally advanced non-small cell lung cancer in the U.S. as of November 1991. Facts on chest irradiation; Survival benefits of adjuvant chemotherapy; Views on the value of adjuvant chemotherapy for patients...

  • Neutropenia and Survival in NSCLC. Ershler, William B. // Clinical Oncology Alert;Dec2009, Vol. 25 Issue 12, p93 

    The article discusses research on the link between the presence of neutropenia and survival in patients with non-small cell lung cancer (NSCLC). It references the study "Chemotherapy-Induced Neutropenia As a Prognostic Factor in Advanced Non-Small Cell Lung Cancer: Results From Japan Mutational...

  • oncology highlights 2008.  // Annals of Oncology;Sep2008 Supplement 8, Vol. 19, p44 

    The article presents abstracts on oncology which include the effectiveness of zoledronic acid in treating premenopausal women with early breast cancer, phase-3 randomised trial of everolimus against placebo in metastatic renal cell carcinoma, and the use of cetuximab and platinum-based...

  • Telik confirms potential of Telcyta in lung cancer treatment.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p20 

    Reports that Telik has presented positive interim results from a phase II trial confirming the clinical activity of Telcyta administered as a single agent in the treatment of patients with non-small cell lung cancer who have failed platinum-containing regimens. Observation of poor prognosis in...

  • Gimeracil/oteracil/tegafur.  // Reactions Weekly;Mar2015, Vol. 1542 Issue 1, p122 

    An abstract of the article "Feasibility trial of postoperative adjuvant chemotherapy with S-1, an oral fluoropyrimidine, for elderly patients with non-small cell lung cancer: Report of the lung oncology group in Kyushu (logik) protocol 0901," by N. Ebi and colleagues is presented.


Read the Article


Sign out of this library

Other Topics